SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: William Partmann who started this subject3/20/2002 1:30:49 PM
From: Icebrg  Read Replies (1) of 10345
 
Elan J/V

Spectral Diagnostics Inc. Announces Presentation Of Clinical Data Supporting Broader Use Of The Endotoxin Activity Assay For Risk Stratification In Severe Sepsis

TORONTO, March 20 /CNW/ - Spectral Diagnostics Inc. today announced the presentation of data arising from its pivotal trial of the Endotoxin Activity Assay (EAA). Results from the MEDIC trial (Multi-center Endotoxin Detection in Critical Illness) were presented at the 22nd International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium. Dr. John Marshall, Professor of Surgery and Director of Critical Care Research, University Health Network, University of Toronto presented data showing that an elevated endotoxin level identifies patients who are at greater risk for infection, greater risk for severe sepsis and more likely to die in the Intensive Care Unit.

Dr. Paul Walker, CEO of Spectral Diagnostics, stated, "Severe sepsis remains a major health care challenge worldwide. Moreover, there has been little or no impact on the mortality rate for severe sepsis in the past 2 decades. Data from the MEDIC trial demonstrated that patients at risk for developing severe sepsis could be identified earlier than with other traditional laboratory tests such as microbial cultures. The EAA provides a rapid and objective test to identify a patient's risk for severe sepsis. Early identification of risk may lead to improved outcomes for these critically ill patients." The economic impact of severe sepsis is substantial with over 16.7 billion dollars spent annually in the United States and similar expenditures for Europe.

Spectral is a developer of innovative technologies for comprehensive disease management. Spectral provides accurate and timely information to the clinician enabling the early initiation of appropriate and targeted therapy. Current products are rapid format tests measuring markers of myocardial infarction (Cardiac STATus(TM) test). The Cardiac STATus(TM) tests are manufactured by Spectral's joint venture partner, Princeton BioMeditech Inc. New products include rapid diagnostics for infection (the Endotoxin Activity Assay). Elan Corporation plc is the joint venture partner of Spectral, and has worldwide commercialization rights to EAA. The EAA is manufactured by Spectral Diagnostics Inc. Spectral's common shares are listed on the Toronto Stock Exchange: SDI.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News